Chief Innovation Officer Honor Health Innovations
Dr Kiran Avancha has over 18 years of strategic and business leadership experience in biotech, healthcare innovation, clinical research and drug development.
He is currently working as the inaugural Chief Innovation Officer of HonorHealth since 2022. Under his leadership, HonorHealth established HonorHealth Innovations (H2I) and an Innovation Investment Fund that invested in 24 start-ups (digital health, diagnostics, medical devices & therapeutics) and continues to grow its portfolio. He is a serial entrepreneur, investor, mentor, and advisor and sits on the boards of couple of the portfolio startups.
He joined HonorHealth in 2015 as the Chief Operating Officer of the Research Institute (HRI), where he led clinical research operations for the health-system, strategic planning for HRI, business development and integration of community-based research practices into HRI. He built global collaboration of HRI with 400+ biotech, pharma, medical devices and life sciences companies.
He is the coFounder & CEO of Prizm Therapeutics, a late-clinical stage pediatric rare disease biotech, that is currently developing a novel therapy for the treatment of pediatric genetic disease called MCT8 deficiency, that is similar to cerebral palsy with high unmet medical need. He successfully launched and sold ClinSync, a full-service CRO based out of India which is now operating in 6 countries.
Dr Avancha is a licensed clinical pharmacist (RPh) and holds PhD in Medicinal Chemistry from the University of South Florida.